Latest Insider Transactions at Regeneron Pharmaceuticals, Inc. (REGN)
This section provides a real-time view of insider transactions for Regeneron Pharmaceuticals, Inc. (REGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of REGENERON PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of REGENERON PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 09
2020
|
Sanofi |
SELL
Open market or private sale
|
Direct |
128,914
-0.63%
|
$63,038,946
$489.65 P/Share
|
|
Feb 27
2020
|
Neil Stahl EVP Research and Development |
SELL
Open market or private sale
|
Direct |
10,349
-2.23%
|
$4,667,399
$451.97 P/Share
|
|
Feb 26
2020
|
George L Sing Director |
SELL
Open market or private sale
|
Indirect |
2,400
-8.34%
|
$1,084,800
$452.83 P/Share
|
|
Feb 26
2020
|
George L Sing Director |
SELL
Open market or private sale
|
Direct |
2,500
-2.12%
|
$1,150,000
$460.0 P/Share
|
|
Feb 26
2020
|
George L Sing Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+2.08%
|
$82,500
$33.42 P/Share
|
|
Feb 26
2020
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
14,651
-40.27%
|
$6,607,601
$451.89 P/Share
|
|
Feb 26
2020
|
Neil Stahl EVP Research and Development |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+40.73%
|
$1,300,000
$52.03 P/Share
|
|
Feb 26
2020
|
Daniel P Van Plew EVP & General Mgr Industrial O |
SELL
Open market or private sale
|
Direct |
15,642
-4.2%
|
$7,117,110
$455.99 P/Share
|
|
Feb 26
2020
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
200
-0.1%
|
$91,000
$455.99 P/Share
|
|
Feb 26
2020
|
Neil Stahl EVP Research and Development |
SELL
Bona fide gift
|
Direct |
750
-3.45%
|
-
|
|
Feb 25
2020
|
Daniel P Van Plew EVP & General Mgr Industrial O |
SELL
Payment of exercise price or tax liability
|
Direct |
17,093
-28.03%
|
$7,640,571
$447.3 P/Share
|
|
Feb 25
2020
|
Daniel P Van Plew EVP & General Mgr Industrial O |
BUY
Exercise of conversion of derivative security
|
Direct |
32,735
+34.93%
|
$982,050
$30.63 P/Share
|
|
Feb 25
2020
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
214
-0.08%
|
$95,872
$448.67 P/Share
|
|
Feb 25
2020
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
800
-3.06%
|
$357,600
$447.3 P/Share
|
|
Feb 25
2020
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+3.68%
|
$272,000
$272.7 P/Share
|
|
Feb 24
2020
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
786
-3.03%
|
$319,116
$406.59 P/Share
|
|
Feb 24
2020
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+3.71%
|
$272,000
$272.7 P/Share
|
|
Feb 24
2020
|
Michael S Brown Director |
SELL
Open market or private sale
|
Direct |
2,000
-40.21%
|
$838,000
$419.01 P/Share
|
|
Feb 24
2020
|
Michael S Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+43.08%
|
$546,000
$273.67 P/Share
|
|
Feb 24
2020
|
George Yancopoulos President and Chief Scientific |
SELL
Open market or private sale
|
Direct |
118,123
-18.58%
|
$49,611,660
$420.17 P/Share
|
|
Feb 13
2020
|
Marc Tessier Lavigne Director |
SELL
Open market or private sale
|
Direct |
14,279
-41.91%
|
$5,697,321
$399.58 P/Share
|
|
Feb 13
2020
|
Marc Tessier Lavigne Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,279
+43.89%
|
$771,066
$54.01 P/Share
|
|
Feb 13
2020
|
Neil Stahl EVP Research and Development |
SELL
Open market or private sale
|
Direct |
10,278
-11.84%
|
$4,131,756
$402.12 P/Share
|
|
Feb 13
2020
|
Robert E Landry EVP Finance CFO |
SELL
Open market or private sale
|
Direct |
107
-0.07%
|
$42,907
$401.79 P/Share
|
|
Feb 12
2020
|
Neil Stahl EVP Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
14,722
-40.47%
|
$5,918,244
$402.34 P/Share
|
|
Feb 12
2020
|
Neil Stahl EVP Research and Development |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+40.73%
|
$1,300,000
$52.03 P/Share
|
|
Feb 12
2020
|
Robert E Landry EVP Finance CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
393
-1.54%
|
$157,986
$402.34 P/Share
|
|
Feb 12
2020
|
Robert E Landry EVP Finance CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+1.93%
|
$136,000
$272.7 P/Share
|
|
Feb 07
2020
|
Joseph L Goldstein Director |
SELL
Open market or private sale
|
Direct |
1,000
-9.4%
|
$382,000
$382.83 P/Share
|
|
Jan 03
2020
|
P Roy Vagelos Director |
SELL
Bona fide gift
|
Indirect |
564
-0.39%
|
-
|
|
Nov 26
2019
|
Arthur F Ryan Director |
SELL
Bona fide gift
|
Direct |
1,000
-3.66%
|
-
|
|
Nov 22
2019
|
Arthur F Ryan Director |
SELL
Bona fide gift
|
Direct |
1,500
-5.2%
|
-
|
|
Sep 10
2019
|
Sanofi |
SELL
Open market or private sale
|
Direct |
172,904
-0.83%
|
$48,586,024
$281.15 P/Share
|
|
Mar 08
2019
|
Sanofi |
SELL
Open market or private sale
|
Direct |
131,115
-0.63%
|
$54,019,380
$412.17 P/Share
|
|
Sep 06
2018
|
Sanofi |
SELL
Open market or private sale
|
Indirect |
104,552
-0.44%
|
$42,448,112
$406.68 P/Share
|
|
Jun 08
2018
|
Sanofi |
SELL
Open market or private sale
|
Indirect |
121,601
-0.51%
|
$37,574,709
$309.31 P/Share
|
|
Aug 25
2017
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
72,378
+0.03%
|
$34,886,196
$482.98 P/Share
|
|
Aug 24
2017
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
105,820
+0.03%
|
$50,899,420
$481.79 P/Share
|
|
Aug 23
2017
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
60,595
+0.05%
|
$28,964,410
$478.3 P/Share
|
|
Jun 02
2017
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
136,050
+0.04%
|
$64,623,750
$475.63 P/Share
|
|
Jan 11
2017
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
87,298
+0.02%
|
$32,387,558
$371.01 P/Share
|
|
Jun 14
2016
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
64,731
+0.04%
|
$23,562,084
$364.22 P/Share
|
|
Feb 17
2016
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
80,000
+0.04%
|
$31,520,000
$394.18 P/Share
|
|
Feb 16
2016
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
81,157
+0.04%
|
$31,651,230
$390.83 P/Share
|
|
Jan 12
2016
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
83,938
+0.02%
|
$38,863,294
$463.51 P/Share
|
|
Oct 06
2015
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
91,578
+0.01%
|
$42,309,036
$462.91 P/Share
|
|
Sep 23
2015
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
147,209
+0.04%
|
$78,315,188
$532.0 P/Share
|
|
Jul 27
2015
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
10,639
+0.0%
|
$5,702,504
$536.74 P/Share
|
|
Dec 24
2014
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
30,002
+0.02%
|
$11,880,792
$396.41 P/Share
|
|
Dec 23
2014
|
Sanofi |
BUY
Open market or private purchase
|
Indirect |
171,457
+0.06%
|
$67,039,687
$391.47 P/Share
|